News from CureVac A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 01, 2014, 09:00 ET

CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

 CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi...

Mar 10, 2014, 15:00 ET

CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize

CureVac, a German clinical stage biopharmaceutical company, today announced that it has won the inaugural European Commission Vaccine Prize. The EU...

Dec 16, 2013, 11:00 ET

CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment

CureVac, a German clinical stage biopharmaceutical company, today announced that it has reached the targeted number of patients for its phase IIb...

Nov 05, 2013, 10:39 ET

1st International mRNA Health Conference in Tuebingen Heralds a New Era in Modern Medicine

The 1st International mRNA Health Conference in Tuebingen on Oct. 23 and 24 brought together for the first time more than 150 attendees from...

Nov 04, 2013, 09:22 ET

CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer

 The non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, a clinical stage biopharmaceutical company...

Oct 03, 2013, 04:00 ET

CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine

 CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on...

Mar 27, 2013, 09:00 ET

CureVac beginnt klinische Phase 2b Studie seines mRNA-basierten Krebsimpfstoffs bei Patienten mit kastrationsresistentem Prostatakrebs

CureVac GmbH, ein biopharmazeutisches Unternehmen, das mit mRNA-basierten Vakzinen eine neue Klasse von Therapien und Impfstoffen zur Behandlung...

Mar 27, 2013, 09:00 ET

CureVac inicia un ensayo clínico de fase 2b de su vacuna contra el cáncer de próstata basada en ARNm

CureVac GmbH, una empresa biofarmacéutica de nivel clínico, pionera en el desarrollo de una nueva clase de tratamientos y vacunas basados...

Mar 27, 2013, 09:00 ET

CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer

 CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on...

Mar 27, 2013, 09:00 ET

CureVac startar klinisk fas IIb-prövning av mRNA-baserat cancervaccin för patienter med kastrationsresistent prostatacancer (CRPC)

CureVac GmbH, ett kliniskt biofarmaceutiskt företag som har banat väg för utvecklingen av en ny klass av terapier och vacciner...

Nov 25, 2012, 13:00 ET

Las vacunas profilácticas ARN(m) mensajero de CureVac demuestran inmunogenicidad frente a la gripe

- Los datos publicados en Nature Biotechnology muestran que las vacunas profilácticas ARN(m) mensajero basadas en la tecnología...

Nov 25, 2012, 13:00 ET

Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac's RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection

 CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German...

Sep 18, 2012, 04:30 ET

CureVac obtient 80 millions d'euros de financement de série D

- Un des plus importants tours de table de financement européens dans le secteur de la biotechnologie  CureVac GmbH, une entreprise...

Sep 18, 2012, 03:00 ET

CureVac Secures EUR80 Million in Series D Financing

 CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, today announced the...

Sep 18, 2012, 03:00 ET

CureVac erhält 80 Millionen Euro in weiterer Finanzierungsrunde

- Finanzierung erlaubt das Erreichen essentieller Meilensteine in Onkologie und Infektiologie - Eine der größten privaten...